- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Clinical trials of enhanced half-life FVIII and FIX – Peter Collins
Dr Collins will review clinical trials of enhanced half-life factor VIII and factor IX. He will offer a personal opinion on these agents could be introduced into routine clinical practice.
Experimental Therapies – Gary E. Gilbert
This presentation will cover the rationale for experimental therapies, including the untested assumptions and projections of the changing clinical standards for efficacy. It will then survey preclinical data for individual therapies and early clinical trial data.
Physicians, trainees and fellows interested in learning about the new and upcoming treatments for hemophilia.
At the conclusion of this activity, I will be able to:
- Understand the rationale for experimental therapies and the untested assumptions that are likely to influence the degree of success.
- Gain knowledge of the preclinical rationale and the early clinical data for experimental therapies that are in trials.
|Geoffrey Barnes, MD||Portola||Consulting|
|Blue Cross Blue Shield of Michigan||Research|
|Chris Ward, PhD||Bayer||Speaker|
|Boehringer-Ingelheim||Speaker, Advisory Board|
|BMS/Pfizer||Speaker, Advisory Board|
|Gary Gilbert||Baxalta||Advisory Board|
|Harvard Med School/VA Healthcare||Inventor|
|Peter Collins||Novo Nordisk||Consultant|
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved.